Millennium Management LLC Takes $1.33 Million Position in Atyr PHARMA INC (NASDAQ:ATYR)

Millennium Management LLC acquired a new stake in Atyr PHARMA INC (NASDAQ:ATYR) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 367,989 shares of the company’s stock, valued at approximately $1,332,000. Millennium Management LLC owned approximately 0.44% of Atyr PHARMA at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in ATYR. JPMorgan Chase & Co. boosted its holdings in Atyr PHARMA by 467.8% during the fourth quarter. JPMorgan Chase & Co. now owns 178,532 shares of the company’s stock worth $646,000 after buying an additional 147,092 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in Atyr PHARMA during the fourth quarter worth approximately $881,000. Charles Schwab Investment Management Inc. bought a new stake in Atyr PHARMA during the fourth quarter worth approximately $144,000. Jane Street Group LLC bought a new stake in Atyr PHARMA during the fourth quarter worth approximately $720,000. Finally, Raymond James Financial Inc. bought a new stake in Atyr PHARMA during the fourth quarter worth approximately $39,000. 61.72% of the stock is currently owned by institutional investors.

Atyr PHARMA Trading Up 13.5%

Shares of ATYR stock opened at $5.39 on Wednesday. Atyr PHARMA INC has a 52-week low of $1.42 and a 52-week high of $5.75. The stock has a market cap of $479.73 million, a price-to-earnings ratio of -5.73 and a beta of 0.79. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. The firm has a fifty day moving average of $3.36 and a 200-day moving average of $3.47.

Atyr PHARMA (NASDAQ:ATYR) last posted its earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.02. On average, equities research analysts forecast that Atyr PHARMA INC will post -0.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ATYR. Leerink Partners assumed coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a research report on Monday, May 19th. Finally, Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $18.60.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.